UNIVERZITETNI KLINICNI CENTER LJUBLJANA

Their core work

University Clinical Center Ljubljana (UKCL) is Slovenia's largest teaching hospital and tertiary care center, providing advanced clinical services across a wide range of medical specialties. In EU research, they contribute clinical expertise, patient cohorts, and real-world hospital data to large-scale multinational health studies. Their H2020 involvement spans infectious disease diagnostics, rare and inflammatory diseases, biomonitoring, and oncology — consistently bringing the clinical translation perspective that bridges laboratory research with bedside application.

What they specialise in

How they've shifted over time

In 2015-2018, UKCL focused on population-level health challenges: biomonitoring chemical exposures (HBM4EU), managing febrile illness to reduce antibiotic misuse (PERFORM), thyroid deficiency prevention (EUthyroid), and Alzheimer's patient engagement (MOPEAD). From 2019 onward, their work shifted toward precision and personalized medicine — RNA-based molecular diagnostics (DIAMONDS), multiomics data integration for rare diseases (ImmunAID, EJP RD), AI-driven ICU surveillance (ENVISION), and precision exercise for childhood cancer (FORTEe). The trajectory clearly moves from broad epidemiological participation toward data-intensive, molecularly targeted clinical research.

UKCL is moving toward data-driven precision medicine — combining molecular diagnostics, AI, and multiomics — making them a strong clinical partner for projects requiring real-world patient data and translational validation.

How they like to work

UKCL operates exclusively as a participant or third party — they have never coordinated an H2020 project, which is typical for large clinical centers that contribute patient access and clinical validation rather than project management. With 345 unique partners across 40 countries, they are embedded in very large multinational consortia (many of their projects are flagship initiatives with dozens of partners). This means they are experienced in multi-site clinical protocols and data sharing within large networks, but prospective partners should expect to lead the coordination themselves.

UKCL has collaborated with 345 unique partners across 40 countries, reflecting their involvement in large pan-European health consortia like HBM4EU and EJP RD. Their network is heavily Western European but spans nearly all EU member states and associated countries.

What sets them apart

UKCL is Slovenia's primary gateway for clinical research collaboration — as the country's largest university hospital, they offer access to diverse patient populations and clinical infrastructure that few other Slovenian institutions can match. Their project portfolio uniquely combines infectious disease diagnostics with rare disease expertise, meaning they can contribute clinical cohorts across a wide disease spectrum. For consortium builders, UKCL brings geographic diversity (Slovenian clinical site) with the reliability of a well-funded tertiary hospital experienced in EU project protocols.

Highlights from their portfolio

• DIAMONDS
  Their largest funded project (EUR 650K) developing RNA-based molecular signature diagnostics for febrile illness — represents their core strength in infectious disease at its most advanced.
• EJP RD
  The European Joint Programme on Rare Diseases is one of the largest health initiatives in H2020, and UKCL's involvement signals their commitment to rare disease infrastructure and FAIR data sharing.
• FORTEe
  An unusual and ambitious project combining paediatric oncology with precision exercise science — signals UKCL's expanding reach into supportive cancer care and quality-of-life interventions.